SPOTLIGHT -
Expert panelists consider the ongoing role of transplant for patients with myelofibrosis and discuss when it is more appropriate to explore systemic therapy options.
Magrolimab Plus Rituximab/Chemo Elicits Deep Responses in Relapsed/Refractory DLBCL
Lunning Lends Insight on Pivotal Data From Pan Pacific Lymphoma 2022
FDA Awards Fast Track Designation to Tamibarotene for Increased-Risk MDS
Sauter and Hill Talk Through CAR T-Cell Sequencing and Access in Lymphomas
UK’s MHRA Approves Zanubrutinib for CLL and MZL
Ibrutinib/Prednisone Provides No CR/PR Benefit vs Placebo/Prednisone in cGVHD
Currently Available Treatment Options for Patients With R/R DLBCL
Overview of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
Both Gastric and Breast HER2 Scoring Algorithms Applicable in mCRC Testing
Encorafenib Plus Cetuximab and Chemotherapy Demonstrates Safety, Efficacy in BRAF V600E–Mutant mCRC